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INTRODUCTION 
 
Cardiovascular disease is a major cause of mortality in patients with 
mild to moderate kidney disease and end stage renal disease[ESRD]. The 
principal reason  to evaluate dyslipidemias in patients with chronic 
kidney disease is to detect abnormalities that may be treated to reduce 
the incidence of cardiovascular disease. 
 
Since chronic Kidney disease is a progressive disease, the various 
lipid abnormalities vary from CKD stages 1- 5 . So it is prudent to look 
into various lipid abnormalities attributed to each stages of kidney 
disease. 
 
In our hospital, there are many patients admitted last year 
fulfilling the criteria for chronic kidney disease and treated as inpatient 
or outpatient. 
 
At present the medical treatment for kidney disease is improving 
and patients long term survival is improving. Peritoneal dialysis, 
hemodialysis and transplantation have revolutioned the prognosis of 
chronic kidney disease in recent time. 
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Although there is still controversy whether CKD represents an 
independent risk factor for incident cardiovascular disease, 
accumulating evidence over the last decade marks out cardiovascular 
disease as major cause of mortality in patients with mild to moderate 
CKD or ESRD. 
 
Dyslipidemia has been established as a well known traditional risk 
factor for cardiovascular disease in the General Population and large 
scale observational studies have shown that patients with impaired 
renal function exhibit significant alterations in lipoprotein metabolism , 
which in their most advanced form may result in the development of 
severe Dyslipidemia. 
 
The Study mainly focuses on the lipid abnormalities attributed to 
different stages of chronic kidney disease. 
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AIM OF THE STUDY 
 
1. To analyze the lipid abnormalities in Patients with Non Diabetic  
Chronic Kidney Disease.  
2. To find the correlation in various stages of Chronic Kidney 
disease with Lipid abnormalities. 
3. To find which lipid abnormalities is more common in the study 
group.  
Inclusion criteria for case selection : 
¾ All newly detected Non diabetic Chronic kidney disease from Sep 
2008 to Sep 2009. 
¾ Age Group 15-65yrs. 
¾ Elevated Renal Parameters with Urea : Creatinine ratio <20 . 
¾ Stable creatinine values taken 4 days apart with variation less than 
20 %. 
¾ Ultrasonographic evidence of Chronic Kidney Disease with kidney 
size less or equal to 9cm . 
¾ Normal Values of LDL< 100mg/dl,HDL <40 [M]<50[F]mg/dl;    
T. Chol<200mg/dl,TGL-150 mg/dl has been taken cut- off range 
for this study. 
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Exclusion criteria for the case selection : 
1. Patients with known h/o diabetes mellitus and patients with 
Diabetic kidney disease , with elevated random blood sugar values 
of >200mg% were excluded. 
2. Ischemic heart disease on treatment already were excluded. 
3. Severe Comorbid conditions like pneumonia, alcoholic Liver 
disease and hypotension . 
4. Those who are taking Beta blocker and thiazide diuretics at time 
of study were excluded. 
5. Patients with H/o intake of anti cholestrelomic agents. 
6. H/O cigarette smoking. 
7. Patients with the features of hypothyroidism and obstructive Liver 
disease. 
8. Patients with previous H/o hemodialysis and peritoneal dialysis. 
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MATERIALS AND METHODS 
 
This study was conducted in Tirunelveli medical college . Patients 
are selected from all Medical wards. By applying the inclusion and 
exclusion criteria, we selected 50 patients for our study among them. 
 
A detailed history was taken for the following symptoms 
suggestive of chronic kidney disease. 
¾ General- Fatigue, Weakness, Pruritus, Bone pain. 
¾ G.I. tract- Anorexia, Nausea, Vomiting. 
¾ Urinary- Nocturia, Polyuria, Oliguria. 
¾ CNS-Numbness, Muscle cramps, Irritability, Hiccough, Seizures 
and Insomnia. 
¾ CVS- Edema, Difficulty in breathing, Chest pain and Giddiness. 
An enquiry for a previous history of diabetes mellitus, 
hypertension, pulmononary tuberculosis, jaundice, renal disease and drug 
intake was made. 
 
The patients were examined clinically for the presence of 
l.Anemia 
2.Edema 
3.Hypertension. 
4.Pericardial rub. 
 5
5.Lung signs. 
6.Asterixis and other CNS signs. 
7.Abdominal Bruit and ascites and 
8.Changes in the Optic fundi: 
The following investigations were done 
¾ Urine  -Albumin 
¾ Sugar 
¾ Deposits 
¾ Culture sensitivity  
Blood- Urea, sugar 
Serum- Creatinine, electrolytes. 
TC,DC,ESR, HB, Platelet count. 
XRay chest PA and abdomen[whenever necessary] Abdominal 
Abdominal Ultrasonogram: This was done in all cases 
Screening for the Ischemic Kidney disease were done with the 
help of Electrocardiogram and the patients who were all taking the anti 
ischemic therapy were excluded, because this treatment alters the serum 
lipid levels. 
Similarly Beta blockers - raises the serum LDL level without 
altering the HDL level. 
Thiazide diuretics - raises the triglyceride level and reduce the 
HDL level. 
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We took the blood sample for lipid profile analysis in fasting state 
in patients with Chronic Kidney Disease who fulfills the following 
criteria. 
Fasting lipid profile is taken because eating raises plasma 
triglycerides, carried mostly in chylomicrons and very low density 
lipoprotein [VLDL] and as result, total cholesterol levels also increase. 
The Postprandial increase in cholesterol and triglycerides are variable, 
depending on the type of food ingested. ln addition, substantial 
variability in postprandial lipid levels is attributable to inherited and 
acquired difference between individuals. 
Methods used to estimate HDL, Total cholesterol and Triglycerides: 
Total Cholesterol- Enzymatic method: 
Principle : cholesterol esters converted to cholesterol and fatty 
acids by cholesterol esterase. 
Cholesterol + O2 → choleston-3one +h2o2.  
2h2o2+phenolic compound → quinonemine. 
The intensity of colured complex produced is directly 
proportional to the concentration of cholesterol content which is 
measured at 505nm with green filter. 
Preparation of working reagent: Dissolve contents of bottle 
labeled 1 cholesterol with quantity of 2 cholesterol suggested on the 
bottle label. Mix gently. 
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Mix standard and sample and incubate for 10mts at 37degree. 
Read absorbance of standard and test at 505nm. 
Test result: interpretated as  
Cholesterol concentration = absorbance of test/absorbance of 
standard ×200.  
HDL cholesterol- Immunoinhibition method: 
This reagent is intended for in-vitro quantitative determination of 
HDL cholesterol in human serum. 
Reagent named as R1,R2 and R3. 
Rl contains goods buffer,4AAP,POD,ascorbate oxidase. 
R2 contains Goods buffer, CHE,CO,F-DAOS 
R3 contains calibrator 
Methodology: 
Anti human Beta -lipoprotein antibody in reagent 1 binds to 
lipoproteins other than HDL. The antigen-antibody complexes formed 
block enzyme reactions when R2 is added. Cholesterol esterase and 
cholesterol oxidase in R2 react only with HDL-C. Hydrogen peroxide 
produced by the enzyme reactions with HDL-C yields a blue coloured 
complex upon oxidase condenstation with F-DAOS in the presence of 
peroxidase.The intensity of the blue colour complex formed at 593nm is 
proportional to the HDL-C in the sample. 
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Triglyceride Estimation :Enzymatic [GPO/Trinder]. 
Reagent composition : 
Reagent 1 TGL Mono reagent. 
LGO611 2×20ml   :  Pipes Buffer 
LGO 621 2×50ml   :  4-chlorophenol 
LGO 631  5 ×100ml :  Magnesium ion 
ATP 
Lipase Peroxidase 
Glycerol kinase 
4-aminoantipyrine 
Glycerol-3-po4 oxidase  
Reagent 2 TG standard 200mg/dl  
LGO 612    l×2.5ml  
LGO  622   l×2.5ml  
LGO   632  2×2.0ml. 
Principle:  The estimation of TGL involves the following enzymatic 
reaction.  
Triglyceride +LPL  →  Glycerol +FFA  
Glycerol + ATP  →  Glycerol -3-phosphatase +ATP 
Glycerol -3 phosphate +02 →DHAP + h2o.  
2H2o2+-DHP → Quinoneimine dye + 4h2o. 
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Absorbance of the quinoneimine dye measured at 505nm is 
directly proportional to TGL concentrations. 
Analysing the sensitivity and specificity of the investigation what 
we used in this study, We used Plasma urea, serum creatinine, creatinine 
clearance and USG abdomen were the necessary investigation to satisfy 
the criteria for the chronic kidney disease. 
 
1) Creatinine Clearance: 
The staging of chronic kidney disease been done by measuring 
creatinine clearance for a minute. 
The renal clearance of the creatinine is the urine creatinine 
excretion divided by the area under the plasma creatinine concentration 
- time curve for the period in which the urine was sampled. The 
creatinine clearance rate more closely resembles the GFR20,15. 
 
The reliability is greatly diminished by 
1. Variability of the tubular secretion of creatinine . 
2. Inability of most patients to collect the urine properly for 24hrs. 
3. Prolonged storage of the urine that falsely rise the urine creatinine 
by 20% 17,19,21. 
In order to obviate the well known difficulties in obtaining a 
complete Urine collection and to have a quick estimate of the GFR when 
urine can not be, nomograms and formulas have been developed. They 
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estimate the GFR via the creatinine clearance predicted from the plasma 
creatinine, body weight, age and gender. 
In this study we used The Cockcroft & Gault [1996] formula for 
estimating predicted creatinine clearance for staging CKD patient29.  
Creatinine Clearance for men in ml/mt =[140-Age] × Body wt / 
S.creat ×72  
Age in years 
Weight in kgs 
Serum creatinine in mg/100ml,for women 85% of the values for men. 
2. Equation from the modification of diet in renal disease 
study[MDRD]. Estimated GFR (mlmin/1.73m2) = 1.86× (Per) -1.154× 
(age )-.2O3
Multiply by 0.742 for women.  
Multiply by 1.21 for African Americans.  
Estimated GFR[eGFR] using the CKD- EPI formula: 
The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 
formula was published in May 2009. It was developed in an effort to create a 
formula more precise than the MDRD formula, especially when actual GFR 
is >60 ml/min per 1.73 m2.18  
Researchers pooled data from multiple studies to develop and validate 
this new equation. They randomly divided 10 studies which included 8254 
participants, into separate data sets for development and internal validation. 
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16 additional studies, which included 3896 participants, were used for 
external validation. 
 
The CKD-EPI equation performed better than the MDRD 
(Modification of Diet in Renal Disease Study) equation, especially at higher 
GFR, with less bias and greater accuracy. When looking at NHANES 
(National Health and Nutrition Examination Survey) data, the median 
estimated GFR was 94.5 ml/min per 1.73 m2 vs. 85.0 ml/min per 1.73 m2, 
and the prevalence of chronic kidney disease was 11.5% versus 13.1%. 
 
The CKD-EPI equation, expressed as a single equation, is: 
GFR = 141 X min(Scr/K,l)α X max(Scr/K, l)-1.209 X 0.993Age X 1.018 
[if female] X 1.159 [if black]17 
 
Where Scr is serum creatinine (mg/dl), K is 0.7 for females and 0.9 for 
males, α is -0.329 for females and -0.411 for males, min indicates the 
minimum of Scr/ic or 1, and max indicates the maximum of Scr/K or 1. 
 
This formula was developed by Levey et al. 
Estimated GFR[eGFR] using the Mayo quadratic formula : 
Another estimation tool to calculate GFR is the Mayo Quadratic 
formula. This formula was developed by Rule et in an attempt to better 
estimate GFR in patients with preserved kidney function. It is well 
recognized that the MDRD formula tends to underestimate GFR in patients 
with preserved kidney function15,20. 
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The other formulas & nomograms in use are 
1 Edward & Whyte (1959) formula 
Creatinine Clearance for men in ml/mt /1.73m2 = 94.3/sr.creat - 
1.8 For women - 85% of the value for men. 
 
2. Jellifes formula 'A'(1971) 
Creat Clearance for men in ml/mt/1.73m2 = 100/sr.creat -12. For 
women = 80/sr.creat -7. 
 
3. Jellifes formula'B'(1973) 
Creatinine Clearance for men in ml/mt/1.73m2= [98-16(age-
20)/20/sr.creat. 
 
 4. Hull (1981) formula. 
Creatinine clearance for men in ml/mt/70kg = 145-
age(yrs)/sr.ceat.-3.  
For women = 0.85(145-Age in yrs)/Sr.creat(mg/dl)28. 
The formula of Cockcroft & gault formula was quoted in over 70 
publications n 1991 and displayed in the 1991 Canadian compendium of 
Pharmaceuticals and specialties as the method of estimating renal 
functions21. 
There are enough published studies in the last 20yrs to reach 
meaningful conclusion about the accuracy of predicting the glomerular 
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functions from the serum creatinine using Cockcroft and gault 
formula17,29.  
Waller et al in 1991 suggested that the predicted creatinine 
clearance provides a simpler alternatives to the measured clearance for 
determining the GFR.25 
 
Advantages : 
¾ Timed urine collection is avoided 
¾ Results are available instantly. 
¾ Cost is reduced to less than half of that of the measured Creat 
clearance29. 
 
Limitations and possible source of error in this methods : 
Age : In children the influence of sex on muscle mass is less important. 
The concentration in serum may rise but the creat clearance adjusted to the 
body surface area may remain unchanged. 
 
Body Morphology :  
Difference between the predicted and the measured creatinine clearance 
clearance are seen in very obese , pregnant women and in those with marked 
muscle wasting. 
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Lack of stable renal function :  
It means that renal function should not have changed greatly over the 
last 4 days. Unstable renal functions is the most frequent problem in the 
critical ill, hospitalized patients. 
 
Creatinine assay:  
Drugs like salicylate, cotrimoxazole and cimetidine can inhibit tubular 
secretion of creatinine and thereby increase the serum creatinine 
concentration without a change in the glomerular function.Ingestion of 
cooked meat and sternuous exercise may increase the serum creatinine 
concentration22,23. 
 
Creatinine secretion:  
The mean ratio of the clearance of Tc-DTPA to the measured creatinine 
clearance was used 1:24 and was 1:13 with the predicted creatinine clearance 
was 13ml/mt for the measured creatinine clearance and 4ml/mt for the 
predicted method very little than the regular 24hrs measured method18. 
 
1) Plasma Urea : 
Plasma urea is poor measure of the GFR . Urea production is  variable 
largely depends on the protein intake. Thus the kidneys excrete most of the 
urea. It can be readily reabsorbed in the tubules .In conditions like low 
antidiuretic harmone levels, the medullary collecting tubules are 
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impermeable to urea.In conditions with low effective intravascular volume 
having high ADH level, the urea reabsorption can be substantial14. 
Substances interfering with the urea estimation- falsely high level are 
aminosalicylic acid level, bilurubin,lipemia,dextran,uric acid ,free 
hemoglobin12,13. 
Falsely low level are Vit C, levodopa and lipids .      
Serum Creatinine: 
It is very insensitive to even substantial decline in GFR. GFR 
measured by most accurate technique may be reduced upto 50% before 
serum creatinine becomes elevated. It is insensitive because 
1. Sr. Creat with muscle mass 
Serum Creat value in young &normal individual indicated The 
normal GFR. The same level in the elderly individual could indicate a 
twofold reduction in GFR. 
2. Proportional tubular secretion of serum creatinine increases with 
the decreasing GFR. 
3. With the declining kidney function extra renal degradation of the 
creatinine increases18. 
Methods used to measure Serum creatinine: 
¾ Original folin-wu method- using jaffe reaction 
¾ Method of Hare- using Lloyd reagent 
¾ The direct Alkaline Pictrate method. 
¾ Auto analyzer using Jaffes reaction25,20. 
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A number of normal plasma constituents can interfere with 
creatinine measurement. They are glucose, pyruvate, acetoacetate, uric 
acid, ascorbic acid and plasma proteins. These normal constituents cause 
Jaffes calorimetric assay to yield high value. These interfering 
chromogens increase the creatinine value by about 20% 23,24.
 
One study has shown that in normal individuals the contributions 
of the nonchromogens in serum creatinine is about 14% and in CKD 
patient non chromogen contribution in creatinine is about 5 %.19 
 
Several modifications in Jaffes reaction have done to remove the 
interfering chromogens. Fuller earth and ion exchange resins used to 
remove the non- chromogens. 
 
These methods are replaced by the costlier and convenient auto 
analyzer technique. These technique perpetuates the creatinine from 
nonchromogens. In our study we utilized the Auto analyzer method26. 
 
Ultrasonogram abdomen : 
The Ultrasonogram features considered evident of chronic renal 
failure were  
1.Small contracted kidney as evidenced by kidney size equal or  less        
than 9 cm. 
2.Poor corticomedullary differentiation. 
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3.Increased echogenicity based upon which the renal parenchymal 
disease was graded as follows 
Grade 0- normal. 
Grade 1- Echogenicity of the renal cortex equal to that of the 
liver. 
Grade 2- Echogenicity of the renal cortex more than that of the 
liver, but less than that of the renal sinus fat. 
Grade 3- Echogenicity of the renal cortex approaching that of the  
      renal sinus fat. 
Statistical Analysis : 
 The Study Subjects were described in terms of percentages and 
mean values according to their sex and age.  The other required analysis 
and inter group variability were made by the respective test of 
significance with the usage of the statistical package S.P.S.S. (13.0) at 57 
level of significance (p=0.05)  
¾ Ethical committee approval obtained.  
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BACKGROUND OF THE STUDY  
 
 In Tirunelveli Medical College, Lipid analysis is done in fasting 
state mainly for patients having risk of poor cardiovascular outcome.  
 
 Experimental and clinical studies have suggested a correlation 
between the progression of renal disease and dyslipidemia.  High Plasma 
cholesterol, LDL and Triglyceride  level and low HDL level have been 
demonstrated to be independent risk factors for progression of renal 
disease from CKD stages 1-5 in humans.  
 
 We conducted this study to evaluate the lipid abnormalities in 
various stages of chronic kidney disease on the background of these 
references.  
 
 We used Cock-Croft & Gault (1976) formula to calculate  the 
predicted creatinine  clearance which is a rough estimation of G.F.R. in 
staging of Kidney disease.  
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REVIEW OF  LITERATURE 
CHRONIC  KIDNEY  DISEASE 
Introduction : 
The prevalence of chronic kidney disease (CKD) in India is estimated 
at 7572 per million and end stage Kidney disease at 757per million 
population, with a staggering financial and social burden. To reduce this 
burden and improve patient outcome ,Chronic Kidney disease should be 
detected and treated before the onset of kidney failure through investigation 
and prompt treatment of CKD3. 
 
Definition of the chronic kidney disease: 
A. Kidney damage for 3 months or longer, as defined by structural or 
functional abnormalities of the kidney, with or without decreased 
glomerular filtration rate manifest by either 
 
1. Pathological abnormalities, 
2. Markers of kidney damage, including abnormalities in the 
composition of the blood or urine or abnormalities in the imaging 
studies. 
B. Glomerular filtration rate less than 60ml per minute per 1.73 
m2 for 3 months or longer with or with out kidney damage9. 
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The Prevalence of chronic kidney disease has increased by 16% from 
the previous decade. The increasing incidence of diabetes mellitus, 
Hypertension (high blood pressure), obesity and aging population have led 
to this increase in kidney disease. 
 
Chronic kidney disease is when one suffers from gradual and 
usually permanent loss of kidney function over time. This happens 
gradually over time, usually months to years. 
 
Kidney failure occurs when the kidneys partly or completely lose their 
ability to carry out normal functions5. 
 
This is dangerous because water, waste, and toxic substances build up 
that normally are removed from the body by the kidneys. 
 
It also causes other problems such as anemia, high blood pressure, 
acidosis (excessive acidity of body fluids), disorders of cholesterol and fatty 
acids, and bone disease in the body by impairing hormone production by the 
kidneys44. 
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CAUSES OF CHRONIC KIDNEY DISEASE 
Major causes : 
Type 1 and Type 2 Diabetes Mellitus 
Hypertension.1 
Other causes : 
¾ Glomerulonephritis 
¾  Lupus nephritis -   Post infectious 
¾ Polycystic Kidney Disease. 
¾ Tubulo Interstitial Nephropathy 
¾ Reflux nephropathy 
¾ Hemolytic uremic syndrome/TTP 
¾ Vasculitis-Wegeners granulomatosis, Polyarteritis nodosa. 
¾ Analgesic nephropathy. 
¾ Ischemic nephropathy[atherosclerosis] 
¾ Obstructive uropathy5 
Rare causes : 
HIV infection, Sickle cell disease, heroin abuse, kidney stones, 
amyloidosis and cancer. 
Risk Factors For CKD: 
¾ Ethnicity 
¾ Gender - male > female 
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¾ Smoking 
¾ Heavy consumption of the non- narcotic analgesics. 
¾ Family history of CVD. 
¾ Increased renin angiotensinogen activity 
¾ Thrombogenic factors- antiplatelet agent.  
Clue to diagnosis of Chronic disease by analyzing History of the 
patient 
l.Review of symptoms : 
Symptoms during urination : usually suggests disorders of urinary 
tract such as Infections, obstructions or stones. 
Recent Infections :  
 Suggests post-infectious glomerulonephritis or HIV associated 
nephropathy. 
Skin rashes or arthritis : 
  Suggests connective tissue disorder like SLE or cryoglobilunemia. 
Risk factors for parenteraly transmitted disease :may suggests HIV , 
Hep B , Hep C or associated kidney disease. 
2.Chronic diseases : 
Heart failure , Cirrhosis, or gastroindestinal fluid losses -usualy 
suggests reduced kidney perfusion. 
Diabetes - starts as microalbminuria then clinical proteinuria  and 
Hypertension31 . 
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Hypertension - Hypertensive nephrosclerosis characterized by severly 
elevated blood pressure followed by end organ damage Recent worsening 
of hypertension in background of diffuse atherosclerosis indicates large 
vessel disease. Recent onset of severe HT in young females suggests 
fibromuscular dysplasia48.  
 
3.Past Medical History : 
Findings from Past routine exam – indicates  proteinuria or HT 
during childhood, during pregnancy, schooling. 
Past urological evaluation - gives details regarding radiological 
abnormalities associated with kidney disease.  
 
4. Family history of Kidney Disease : 
 
Every generation, equal susceptibility to male and female- indicates 
autosomal dominant disease like polycystic kidney disease. 
 
Every generation, male susceptibility- indicates sex linked 
recessive disorder like Alports syndrome. 
 
Less frequent than every generation - indicates autosomal recessive 
disease like medullary cystic disease or Autosomal recessive Polycystic 
kidney disease5. 
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Types and Examples of Risk factors for chronic Kidney diseases1. 
 
 
 Definition Examples 
Susceptibility 
factors 
Increase susceptibility to 
kidney damage 
Older age, family history 
Initiation 
factors 
Directly initiate kidney 
damage 
DM. High BP, autoimmune
disease, systemic infection. 
UTI, urinary stone, drug
toxicity 
Progression 
factors 
Cause worsening kidney 
damage and faster decline 
in kidney function after 
initiation of kidney
damage . 
Higher level of proteinuria; 
High BP, poor glycemic 
control in DM, smoking. 
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STAGES OF CHRONIC KIDNEY DISEASE10 : 
Stage Description GFR        
ml per m2 
Prevalence  in 
(%) 
Action 
- At increased risk >60ml(CKD 
risk factors) 
-   CKD risk 
reduction 
1 Kidney   damage 
with normal    or 
increased GFR 
>90 5,900,000(3.3) Diagnosis         
and treatment: 
treatment of the 
comorbid   
condition. 
Slowing            
the progression 
2 Kidney   damage 
with slightly 
decreased GFR 
60-89 5.300,000(3) Estimating the 
progression 
3 Moderately    
decreased GFR 
30-59 7,600,000(4.3) Evaluating and 
treating the 
complication 
4 Severely        
decreased GFR 
15-29 400,000(0.2) Preparation for 
kidney 
replacement 
therapy 
5 Kidney failure < 15 300,000 Kidney 
replacement. 
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Prevalence of GFR Categories in Adults 
Age Group (yr) 
GFR 
mL/min/1.73 m 20-39 40-59 60-69 570 
>90 86.0% 55.7% 38.5% 25.5% 
60-89 13.7% 42.7% 53.8% 48.5% 
30-59 a 1.8% 7.1% 24.6% 
15-29 a a a 1.3% 
N (millions): 82 55 20 20 
 
GFR estimated from serum creatinine using MDRD Study equation 
based on age, gender, race and calibration for serum creatinine. Data from 
NHANES III (1988-1994). N = 15,000. Based on one-time assessment of 
estimated GFR. 
Fewer than 20 cases; data not considered reliable. 
KDOQI Guidelines for Normal GFR in various age groups10 
Normal GFR in Children and Young Adults 
Age (Sex) Mean GFR±SD(mL/min/1.73 m*) 
1 week (males and females) 4O.6 ±14.8 
2—8 weeks (males and females) 65.8 ±24.8 
>8 weeks (males and females) 95.7 ±21.7 
2—12 years (males and females) 133O±27.O 
13—21 years (males) 14O.O ±3O.O 
13—21 years (females) 126.O ±22.0 
*Data based on three studies. 
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Abbreviation: SD, standard deviation 
Clinical situations in which creatinine clearance may be necessary 
to measure GFR 
1. Extremes of age and body size 
2. Severe malnutrition or obesity 
3. Disease of skeletal muscle. 
4. Paraplegia or quadriplegia. 
5. Vegetarian diet. 
6. Rapidly changing kidney function 
7. Prior to dosing drugs with significant toxicity, that are excreted by 
kidneys. 
 
Lipoprotein Metabolism: 
Lipids circulating in Plasma are incorporated into spherical, water 
soluble particles [lipoproteins]that contain a core of nonpolar  lipids 
[cholesterol, cholesterol ester and triglycerides] surrounded by a 
monolayer composed of specific proteins, polar lipids and esterified 
cholesterol and phospholipids9. 
 
The Protein components of lipoproteins are called apoproteins. 
Some of these apoproteins, such as apoprotein A-l in HDL, apoprotein B-
100 in LDL, and apoprotein B-48 in chylomicrons. 
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Metabolic function of Plasma Apoproteins: 
Apoproteins Metabolic Role 
A-l Activates LCAT 
A-11 Activates hepatic lipase;may inhibit 
LCAT 
A-lV unknown 
B-48 Transport of lipids from the gut as 
chylomicrons. 
B-100 Transport of lipids from the Liver as 
VLDL and LDL 
C-1 Activates LCAT 
C-11 Activates Lipoprotein Lipase. 
C-lll May inhibit activation of lipoprotein 
lipase by apoC-11
D May be involved in lipid transfer 
between lipoproteins. 
E Recognised by hepatic apo E receptors 
and cellular receptors; 
Cholesterol Transfer protein Facilitates the exchange of cholesterol 
esters and TGL between HDL and 
VLDL and LDL.
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Four enzymes play pivotal role in lipid metabolism: 
¾ Lipoprotein Lipase  
¾ Hepatic triglyceride lipase  
¾ Lecithin-cholesterol acyltransferase  
¾ Cholesteryl ester transfer protein32,16. 
The major action of Lipoprotein lipase is to degrade TGL rich 
particles in the postprandial state. 
Hepatic lipase has 2 major actions : l] hydrolysis of TGL and 
phospholipids of HDL2.and2]hydrolysis of TGL of VLDL and IDL. 
Hepatic lipase catalyzes hydrolysis and removal of the 
triglyceride content of HDL. Thus hepatic lipase deficiency can 
potentially contribute to increased HDL, triglyceride content. In fact, 
as described later (abnormalities of lipoprotein remnants), CRF results 
in pronounced hepatic lipase deficiency in humans and experimental 
animals33,34. 
The enzyme LCAT, which is synthesized in the liver, catalyses the 
formation of cholesterols esters in the plasma by transferring a fatty acyl 
chain from phospholipids to the hydroxyl group of unesterified 
cholesterol. 
LCAT plays an important role in HDL-mediated cholesterol 
uptake from the extrahepatic tissues and, as such, serves as a main 
determinant of HDL maturation and plasma HDL cholesterol level. 
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Thus LCAT deficiency can potentially account for diminished plasma 
HDL cholesterol and impaired HDL maturation in CRF. In fact, plasma 
LCAT activity is consistently diminished in patients with ESRD. This 
is accompanied by a significant elevation of plasma-free cholesterol 
and a marked reduction in plasma esterified cholesterol concentration, 
providing functional evidence for diminished LCAT-dependent 
cholesterol esterification33,34. 
The specific transfer protein, CETP, facilitate exchange of 
cholesterol esters and TGL between HDL and VLDL and LDL 
CETP mediates transfer of cholesterol ester from HDL to IDL in 
exchange for triglycerides. Thus a potential increase in plasma CETP 
can contribute to the CRF-associated reduction in HDL cholesterol 
ester and elevation of HDL triglycerides. In fact, according to a recent 
study, more than 34% of hemodialysis-dependent patients were found 
to have high plasma CETP levels. The mechanism responsible for the 
reported elevation of CETP in ESRD patients is unknown and requires 
future investigation. The effect of CRF is amplified by proteinuria, 
which has been shown to increase synthesis and markedly raise plasma 
concentration of CETP. Thus plasma CETP is expectedly elevated in 
patients with heavy proteinuria and mild to severe renal 
insufficiency39. 
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Metabolism of Very Low density Lipoproteins: 
The Liver is the main site of VLDL synthesis . VLDL particles transport 
endogenous TGL from the liver to peripheral tissues. The Intravascular 
hydrolysis of VLDL, TGL depends on the activity of Lipoprotein Lipase. LDL 
is the major product of VLDL metabolism in Human plasma. Diet, freefatty 
acids, plasma concentration of insulin, glucagon, and epinephrine modulate 
the secretion of VLDL16 
 Friedewald formula to calculate LDL: 
The Friedewald formula appears to be the most practical, reliable 
method for determining LDL cholesterol in clinical practice:                            
LDL = Cholesterol - HDL- (triglycerides ÷ 5), in mg/dl, or                            
LDL = Cholesterol-HDL- (triglycerides÷2.19), in mmol/l32. 
Two recent studies found the Friedewald formula to be reliable in 
dialysis patients, although other investigators reported that the percentage 
error for the formula is higher in patients with CKD compared to the general 
population. No studies have examined the accuracy of the Friedewald formula 
in transplant recipients, or studies in other CKD patients, eg, those with 
nephrotic syndrome. 
Recent data from a study in the general population suggest that the 
Friedewald formula may underestimate LDL in patients with low LDL levels. 
Data from the general population also suggest that the Friedewald formula is 
not accurate when triglycerides are >400 mg/dl (>4.52 mmol/l). Direct 
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measurement of LDL with ultra-centrifugation or immunoprecipitation 
techniques is reasonably accurate when triglycerides are 400-800 mg/dl 
(4.52-9.03 mmol/l), but there are no reliable techniques for determining LDL 
when triglycerides are >800 mg/dl ( > 9.03 mmol/l). Fasting triglycerides 
>800 mg/dl (>9.03 mmol/l) generally indicate the presence of 
hyperchylomicronemia, and the role of hyperchylomicronemia in ACVD is 
unknown36. 
There are few studies in children, and none included children with CKD. 
However, in 1 study of children from the general population, calculating LDL 
using the Friedewald formula was more reliable in correctly classifying 
patients with high LDL than was the direct measurement. 
LDL is the major cholesterol carrying particle present in the 
plasma. The liver accounts for 70% of the catabolism of LDL and 
peripheral tissues account for the remaining 30%.The uptake of LDL by 
receptor mediated endocytosis cholesterol biosynthesis, an enhanced rate 
of intracellular cholesterol esterifications, and a reduction in the number 
of High affinity LDL receptors expressed on the cell surface30. 
Metabolism of High density-Lipoprotein: HDL is generated in 
the liver from the intravascular lipolysis of VLDL particles and 
chylomicrons. The newly synthesized HDL contains predominantly 
protein, free cholesterol, and phospholipids. The apoprotein content of 
individual HDL particles differs. Some HDL particles contain apo A-
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1[HDL2] and apo A-11[HDL3]. Some contains only apo A-l. The half life 
of HDL is for 4-6days. Epidemological studies in the general population 
documented an inverse relationship between Plasma HDL cholesterol 
concentration and risk of coronary heart disease33,16. 
Hepatic SRB-1 is the primary pathway for disposal of HDL-
borne cholesterol ester and triglycerides. Therefore, potential 
dysregulation of this protein can impact HDL metabolism. Heavy 
glomerular proteinuria has been shown to significantly reduce hepatic 
SRB-1 protein expression in experimental animals. In contrast, CRF 
per se, without heavy proteinuria, induced by nephrectomy, does not 
significantly change SRB-1 mRNA or protein abundance in the liver. 
However, concomitant heavy proteinuria and renal insufficiency may 
affect SRB-1 expression and hence, HDL-mediated reverse cholesterol 
transport16. 
HDL-mediated cholesterol uptake from the extrahepatic tissues 
depends on deesterification of cholesterol esters contained in the 
intracellular vesicles and the resultant release of free cholesterol. This 
process is opposed by ACAT, which is the main enzyme for 
intracellular esterification of cholesterol. Therefore, a relative 
increase in ACAT activity can potentially limit HDL-mediated 
cholesterol uptake and, hence, contribute to the reduction in plasma 
HDL cholesterol and impaired maturation of HDL. Although the effect 
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of CRF on ACAT expression and activity in the extrahepatic tissues is 
not known, CRF has been recently shown to markedly raise hepatic 
ACAT-2 mRNA and protein abundance, as well as total ACAT 
activity33,16. 
 The potential contribution of ACAT to the CRF-induced 
dysregulation of HDL metabolism was illustrated by a recent study 
which revealed that pharmacological inhibition of ACAT results in a 
dramatic shift in plasma cholesterol from apoB-containing 
lipoproteins to HDL with virtually no change in plasma total 
cholesterol in CRF animals. Interestingly, the improvement in the 
lipid profile with an ACAT inhibitor was accompanied by a 
significantly higher creatinine clearance in the treated than the 
untreated animals. This phenomenon may be due to amelioration of 
dyslipidemia and enhanced HDL-mediated reverse cholesterol 
transport, leading to attenuation of glomerulosclerosis. 
Abnormalities of Lipoprotein metabolism in Chronic Kidney disease. 
The dyslipidemia found in CKD patients is usually secondary to 
their renal disease. The family history provide link to genetic component. 
Some lipid abnormalities are demonstrable in patients with renal disease 
even when GFR is normal. But disorders of lipoprotein metabolism 
increase in frequency and severity as renal insufficiency develops. 
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The most frequent constellation of lipid abnormalities in CKD 
comprises a decrease in HDL- cholesterol, an increase in VLDL andIDL 
cholesterol, as well as normal  LDL- cholesterol [reflects a redistribution 
of cholesterol from HDL to VLDL and IDL]. The ratios of Total 
cholesterol /HDL cholesterol and LDL cholesterol /HDL cholesterol are 
usually increased16,33 . 
The reduced level of HDL reflects reduction of both HDL 2 and 
HDL 3 subfractions. In CKD, a defect in cholesterol transport, probably 
due to diminished LCAT activity and increased activity of CETP, have 
been documented. The recently proposed index of NON HDL 
cholesterol, reflecting the sum of LDL and VLDL particles appears to be 
more sensitive and is a superior predictor of cardiovascular risk. 
Hypertriglyceridemia is commonly found in CKD and is the result 
of both increased synthesis of TGL and VLDL apo B-100 apoprotein in 
the liver and decreased catabolism of VLDL. Increased TGL and VLDL 
apo B 100 synthesis in the liver were documented in animal experiments 
and in CKD patients. 
Quantitative changes in Plasma Lipid Profile: 
1. Moderate elevation of Plasma TGL concentrations.  
2. Low plasma HDL-cholesterol concentrations.  
3. High Plasma VLDL and IDL- cholesterol 
4. Normal or increased LDL cholesterol 
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The activity of lipoprotein lipase in plasma and in adipose tissue is 
decreased in animal experiments and in patients with CKD, even when 
the plasma TGL is normal. The activity of lipoprotein lipase is 
influenced by apolipoprotein isoforms, apoprotein C -11 activates and 
apoprotein C-lll inhibits lipoprotein lipase activity. A decreased ratio 
of apo C-ll and apo C-lll is observed even in early stages of CKD. 
Reduced activity of lipoprotein lipase explains the disturbed first step in 
the breakdown of both chylomicrons and of VLDL . Because of reduced 
activity of hepatic TGL lipase, the clearance of partially metabolised 
lipoproteins and chylomicrons is disturbed as well7. 
Aporprotein abnormalities in CKD: 
The concentrations of apo A-l and apo A-ll are decreased. In 
hemodialysis patients it has been documented that decreased apo A1 
levels are due to an increased rate of catabolism, whereas reduced apo 
A-ll levels are primarily due to decreased rate of production. These 
apoprotein abnormalities are more marked in patients with advanced 
renal insufficiency and in patients with hypertriglyceridemia. The apo B 
concentrations are usually normal in early stages of CKD and are 
minimally elevated, at best in patients with advanced renal 
insufficiency. The ratio of apoA-l/C-111 and apo A-l/B are reduced, 
and the ratio of apoC-lll/apoE is increased. Similar abnormalities of apo 
B,C-111 and E concentrations can also be found7,8. 
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Qualitative Lipoprotein changes in CKD: 
Post ribosomal modification of apolipoproteins by oxidation, 
glycation and carbamylation. Oxidation does not reduce the affinity of 
oxidized LDL to the scavenger receptors and oxidized LDL uptake by 
the macrophage scavenger receptor is increased favouring foam cells. 
Oxidised LDL exhibits additional atherogenic properties including 
cytotoxicity and stimulation of thrombotic as well as inflammatory 
events.HDL protects against the oxidation of LDL. In hemodilayis patient 
the capacity of HDL patients to prevent LDL oxidation is reduced. The 
acute phase response changes the HDL composition , transforming HDL 
from an antioxidant to a pro-oxidant lipoprotein. The reported 
alterations include an increase in apolipoprotein and serum amyloid A 
and a decrease paraxonase activity and Platelet activating factor. Serum 
paraxonase activity reduced in patients with CKD. 
IDL, an intermediate of VLDL catabolism accumulates in CKD 
patients. The IDL concentration is a predictor of severity or progression 
of atherosclerosis. 
LDL particles are heterogenous in size and density. No correlation 
was found between LDL concentration and LDL size. Small dense LDL 
accumulate even in early stages of CKD, when total plasma cholesterol 
and TGL concentrations are still normal47. 
 
 38
Several theories have been proposed regarding the link between 
small dense LDL and atherogenicity. l] Their decreased affinity to the 
LDL receptor combined with their clearance with the scavenger 
receptor. 2]Their increased susceptibility to oxidation and glycation. 
3]Their increased transcapillary escape because of smaller particle size16. 
In CKD patients, Clearance of Chylomicrons is severly impaired.lt 
has been postulated that postprandial persistence of chylomicrons in the 
circulation causes endothelial damage and promotes atherosclerosis. 
This abnormality may contribute to hypertriglyceridemia in CKD5,7. 
LP[a] lipoprotein is a plasma lipoprotein , which contains a protein 
component called apo[a]. In the general population Lp[a] in high 
concentration associated with increased cardiovascular risk. ln patients 
with CKD, prospective studies on the influence of plasma Lp[a] 
concentrations on atherosclerotic complications have yielded conflicting 
results9. 
Progression of renal disease in relation to dyslipidemia: 
Hyperlipidemia can potentially accelerate progression of renal 
disease by several mechanisms. First, reabsorption of fatty acids, 
phospholipids, and cholesterol contained in the filtered proteins 
(albumin and lipoproteins) by tubular epithelial cells can stimulate 
tubulointerstitial inflammation, foam cell formation, and tissue 
injury. Second, accumulation of lipoproteins in glomerular 
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mesangium can promote matrix production and glomerulosclerosis. 
In this context, native and oxidized lipoproteins, particularly LDL, 
stimulate production of matrix proteins by cultured mesangial cells 
and promote generation of proinflammatory cytokines, which can 
lead to recruitment and activation of circulating and resident 
macrophages. In addition, impaired HDL-mediated reverse 
cholesterol transport can further contribute to tissue injury by 
limiting the unloading of the excess cellular cholesterol and 
phospholipid burden. In fact, low plasma HDL has been identified as 
an independent risk factor for progression of renal disease. Moreover, 
hereditary LCAT deficiency, which is associated with a marked 
reduction in HDL cholesterol and impaired HDL-mediated reverse 
cholesterol transport, results in progressive renal disease. It is of note 
that both chronic renal insufficiency and nephrotic syndrome lead to 
acquired LCAT deficiency and impaired HDL metabolism. Correction 
of these abnormalities by ACAT inhibitor administration has been 
shown to reduce proteinuria and retard progression of renal disease in 
experimental animals43,44. 
In addition to the animal studies, a number of clinical studies 
have provided evidence for the potential contribution of dyslipidemia 
in progression to renal disease. For instance, the Physicians Health 
Study demonstrated a significant increase in the risk of deterioration 
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of renal function among individuals with mildly elevated baseline 
serum creatinine who had elevated serum cholesterol and/or reduced 
HDL cholesterol concentrations. Similarly, the Modification of Diet in 
Renal Disease (MDRD) study identified low plasma HDL cholesterol as 
an independent risk factor for progression of renal disease. Together, 
these observations have prompted a limited number of clinical trials 
exploring the effect of lipid-lowering agents in humans with chronic 
kidney disease (CKD). 
Changes in proteinuria, GFR, and treatment of CKD may alter 
lipoprotein levels. Therefore, it is prudent to evaluate dyslipidemias 
more often than is recommended in the general population. Lipoprotein 
levels may change during the first 3 months of hemodialysis, peritoneal 
dialysis, and kidney transplantation. On the other hand, waiting 3 
months to measure the first lipid profile may needlessly delay effective 
treatment for patients who present with dyslipidemia35. For patients 
whose lipid profile is normal at presentation, it is reasonable to repeat 
the lipid profile 3 months later, to confirm that the initial values were 
not low due to malnutrition or systemic disease. During the course of 
kidney disease treatment, lipid levels may change. Therefore, the Work 
Group recommends measuring subsequent levels at least annually. 
Reasons to repeat lipid measurements after 2-3 months include changes 
in kidney replacement therapy modality, treatment with diet or lipid-
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lowering agents, immunosuppressive agents that affect lipids (eg, 
prednisone, cyclosporine, or sirolimus) or other changes that may affect 
plasma lipids39. 
Dyslipidemia in adolescents 
Young adults (20-40 years old) with Stage 5 CKD have at least a 
10-fold higher risk for CVD mortality compared to the general 
population. There are limited data on ACVD in children with CKD. 
However, CVD accounts for approximately 23% of deaths in children 
and adults <30 years old who started treatment for stage 5 CKD as 
children. Recent data from the Pathobiological Determinants of 
Atherosclerosis in Youth (PDAY) study provide compelling evidence in 
the general pediatric population, that initial fatty streaks seen in 
adolescents develop into atheromatous plaques in young adults. 
Moreover, this atherosclerotic process is believed to be accelerated in 
uremia, thus putting children with Stage 5 CKD at high risk for 
developing ACVD. Indeed, studies of arteries from children with Stage 5 
CKD have demonstrated early ACVD changes10. 
Dyslipidemia in Acute Medical conditions : 
Some acute medical conditions may transiently alter plasma lipid 
levels . For example, severe infections, surgery and acute myocardial 
infarction are often associated with lower-than-normal lipid levels. Other 
conditions, for example acute pancreatitis, may be associated with higher 
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levels. In general, it is best to wait until acute conditions that may alter lipid 
levels have resolved before assessing dyslipidemias for possible ACVD risk. 
It should be noted, however, that the lipid profile is not significantly altered 
within the first 24 hours after a myocardial infarction, and a lipid profile can 
be measured during this time31. 
Acute condition 
Total 
cholesterol 
LDL HDL Triglycerides
Myocardial infarction  ↓ ↓ ↓ NC 
Stroke ↓ ↓ NC NC 
Bacterial sepsis &surgery. ↓ ↓ ↓ ↑ 
Acute pancreatitis. ↑ NC NC ↑ 
Tranplant acute rejection  ↓ ↓ NC ↓NC 
Transplant CMV infection  ↓ ↓ NC ↓ 
Abbreviation, LDL-Low density lipoprotein, HDL-High density 
lipoprotein, NC-No change, CMV- Cytomegalovirus. 
Fasting: 
Eating raises plasma triglycerides, carried mostly in chylomicrons 
and very low-density lipoprotein (VLDL), and, as a result, total 
cholesterol levels also increase. The post-prandial increases in 
triglycerides and cholesterol are quite variable, depending on the type of 
food ingested. In addition, substantial variability in postprandial lipid 
 43
levels is attributable to inherited and acquired differences between 
individuals. Although these differences affect the risk for ACVD, the 
relationship between post-prandial lipid levels and ACVD is not as well 
established as the relationship between fasting lipid levels and ACVD.3 
Practical considerations may make non-fasting measurements the only 
alternative for some patients. While fasting lipid profiles are best, it is 
better to obtain non-fasting lipid profiles than to forgo evaluation 
altogether. If the lipid profile obtained in a non-fasting patient is normal, 
then no further assessment is needed at that time. However, an abnormal 
lipid profile in a non-fasting patient is an indication to obtain a fasting 
lipid profile44,49. 
Urine protein excretion, especially if >3 g per 24 hours, can also 
cause or contribute to dyslipidemias. Therefore, CKD patients who still 
produce urine should have protein excretion measured, if this has not 
been done recently. In some cases, the underlying cause(s) of the 
proteinuria can be treated and effectively reversed. In other cases, 
angiotensin II converting enzyme inhibitors or angiotensin II receptor 
blockers may help reduce protein excretion, and may thereby improve the 
lipid profile in some patients. Clinical hypothyroidism can cause 
dyslipidemia, and even subclinical hypothyroidism may cause mild 
changes. Some of the signs and symptoms of hypothyroidism may 
resemble those of uremia, which may make the clinical diagnosis of 
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hypothyroidism more difficult in patients with CKD. Glucose intolerance 
can also cause dyslipidemias. Therefore, patients with dyslipidemia and 
CKD (but without known diabetes) should be assessed with fasting blood 
glucose and possibly glycosylated hemoglobin. Glycemic control can 
improve lipid profiles32. 
Causes of Secondary Lipedemia: 
Nephrotic syndrome, hypothyroidism ,diabetes ,excessive alcohol 
ingestion, and chronic liver disease Medications that can cause 
dyslipidemias include 13-cis-retinoic acid, anticonvulsants, highly active 
anti-retroviral therapy, beta-blockers, diuretics, androgens/anabolic 
steroids, oral contraceptives, corticosteroids, cyclosporine, and sirolimus . 
The assessment of these secondary causes with history, physical 
examination, and appropriate laboratory testing is recommended for any 
patient with dyslipidemia, since effective correction of these disorders 
may improve the lipid profile10. 
Other causes of secondary lipidemia in adolescent and young adults : 
Lipodystrophy; Idiopathic hypercalcemia glycogen storage 
diseases; cystine storage disease; Gaucher disease; Juvenile Tay-Sachs 
disease; Niemann-Pick Disease; sphingolipidoses; obstructive liver 
disease such as biliary atresia; biliary cirrhosis; intrahepatic cholestasis; 
nephrotic syndrome; anorexia nervosa; progeria; systemic lupus 
erythematosus; Werner syndrome; and Klinefelter syndrome. These 
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conditions are fortunately rare, and require referral to appropriate tertiary 
care specialists5. 
Uses of Statins in Early stage of Kidney disease : 
Although the pattern of dyslipidemia with low HDL and elevated 
triglycerides would be a classic indication for fibrates, fibrates have not 
been popular in the renal community. This is mainly because most 
fibrates or their active metabolites accumulate in renal failure and 
occasionally cause rhabdomyolysis. Alternative interventions, such as 
dietary changes or switching to polyunsaturated fatty acids, carry a 
considerable risk of malnutrition or are difficult to implement. The 
nephrologist is thus left with cholesterol-lowering drugs, such as statins 
or ezetimibe. Potential indications for statins in patients with renal 
disease might be to assist in the reduction of proteinuria or to reduce the 
rate of loss of glomerular filtration (progression) apart from the goal to 
reduce cardiovascular events37,51. 
  Meta-analyses of participants with cardiovascular disease in 
randomized controlled studies with statins who had impaired renal 
function and/or proteinuria show a modest, though statistically significant 
reduction in the loss of eGFR with statins (except in patients with diabetic 
nephropathy or glomerulonephritis) as well as a modest, significant 
reduction of proteinuria or albuminuria.  
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More convincing are findings concerning the effect of statins on 
cardiovascular endpoints in patients with the initial stages of CKD (CKD 
stage 2 or early CKD stage 3). The effect of statins has been analyzed in 
several subgroups of patients with elevated serum creatinine who 
participated in prospective intervention trials on the effect of statins in 
patients with high cardiovascular risk. Post hoc analyses in these 
subgroups with impaired GFR suggest that the benefit is at least as high, 
if not higher, in patients with CKD compared with patients without CKD. 
A similar effect was observed in the subgroup of patients with diabetic 
kidney disease. Significant benefit with respect to lowering 
cardiovascular events is seen in patients with CKD (stage 2 and stage 3) 
based on serum creatinine concentration and eGFR. In the Cholesterol 
and Recurrent Events (CARE) study, this was restricted to patients with 
GFR <40 ml/min with or without proteinuria37. 
Use of Statins in Late Stage of Kidney disease : 
Currently, there is a complete lack of controlled information on the 
effects of statin treatment on outcome in patients with advanced CKD 
(stage 4). In the past, information on use of statins in dialysis patients had 
also not been uniform. In an observational study, based on U.S. Renal 
Data System data, Seliger et al found better survival in a small subgroup 
of statin users (n= 362) compared with nonstatin users (n = 3354). More 
recently, in an open prospective randomized study of a small group of 
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patients (n = 143) followed over 20 mo, Holmberg et al. found that 
Atorvastatin had no significant effect on primary cardiac endpoint in 
patients on dialysis whereas an effect was seen in individuals with pre-
end-stage renal disease, potentially suggesting that one may be too late 
when starting statin treatment if the patient is ready for dialysis51. 
The cumulative incidence of primary composite cardiovascular 
endpoints comprising death from cardiac causes, fatal stroke, nonfatal 
myocardial infarction, or nonfatal stroke was not significantly lower over 
an average observation period of 4 yr (relative risk reduction 8%, 0.77 to 
1.10, not significant). There was a positive result, however, for the 
secondary endpoint of all combined cardiovascular events (205 versus 
246 cases in Atorvastatin versus placebo-treated patients, relative risk - 
0.82, P = 0.03). It remains unclear whether these data in diabetic patients 
can be generalized or extrapolated to nondiabetic patients. This will be 
clarified by two ongoing trials (a study to evaluate the use of 
Rosuvastatin in subjects on regular dialysis: an assessment of survival 
and cardiovascular events [AURORA] and Study of Heart and Renal 
Protection [SHARP])38,53. 
Even in early stages of CKD, the cardiovascular risk is 
dramatically increased. In our opinion, the data from post hoc analyses of 
past statin trials on subcohorts of patients in the early stages of CKD 
(CKD stage 2 or early CKD stage 3) are sufficiently suggestive to justify 
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administration of statins. It is our opinion that statins are indicated in 
these patients based on these above post hoc analyses. It has even been 
argued that CKD should be considered a coronary heart disease 
equivalent, although the magnitude of excess cardiovascular risk in early 
CKD undoubtedly needs further assessment. 
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OBSERVATIONS & RESULTS 
Results: 
Evaluation of the study clients: 
 The study subjects were evaluated according to their demographic, 
physiological and bio-chemical characteristics related to chronic kidney 
disease. 
Table -1 Percentage distribution of sex wise study subjects according 
to their age. 
Male Female Total Age group 
(yrs) No % No % No % 
15 – 29 1 2.0 3 6.0 4 8.0 
30 – 44 8 16.0 3 6.0 11 22.0 
45 – 59 16 32.0 6 12.0 22 44.0 
60 and above 8 16.0 5 10.0 13 26.0 
Total 33 66.0 17 34.0 50 100.0 
 
 The above table -1 shows that 44% of C.K.D. patients were in the 
age group between 45-59. Among them the male and female contribution 
were 22% and 12% respectively. The mean age of the total subsets was 
49.8 13.5yrs. The mean ages of male and female subjects were 50.9 + 
12 and 47.7 ±  16.2 years respectively. The observed difference of mean 
ages between the sexes was not statistically significant (P>0.05). 
±
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Table -2 Sex wise  Evaluation of physiological and biochemical 
characteristics of study participants. 
Male Female Total Characteristics 
n Mean S.D n Mean S.D 
Mean 
difference 
‘t’ d.f Signi 
ficance Mean S.D 
Body.wt 33 63.4 6.3 17 55.4 8.4 8.0 3.524 48 P<0.01 60.7 8.5 
Bl. Sugar 33 90.5 17.9 17 98.9 19.0 8.4 1.539 48 P>0.05 93.4 18.6 
Urea 33 120.3 71.9 17 109.5 48.9 10.7 0.552 48 P>0.05 116.6 64.9 
Creatinine  33 6.8 5.6 17 5.8 4.2 1.0 0.606 48 P>0.05 6.5 5.2 
d.f. Degree of freedom, S.D – standard deviation  
 
 The above table -2 evaluates the study participants according to 
their body weight, Bl sugar, urea and creatinine. Except body weight, the 
other variables like Bl. Sugar, urea and creatinine were not significantly 
different between the sexes (P>0.05). The mean body weights of male 
and female were 63.4 ±  6.3 kg and 55.4 ±  8.4kg. The difference was 
statistically highly significant (P<0.01). The total C.K.D. patients mean 
body weight was 60.7  8.5kgs. The mean Bl. Sugar was 93.4 ± ±  
18.6mg/dl. The mean urea and creatinine were 116.6 ±  64.7 and 6.5 ±  
5.2 respectively. 
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 Table -3 Sex wise percentage distribution of hypertensive changes in 
fundus. 
Male Female Total Funds 
changes No % No % 
Significance 
No % 
Normal 7 31.8 3 33.3 P>0.05 10 32.3 
Grade I 9 40.9 3 33.3 P>0.05 12 38.7 
Grade II 6 27.3 3 33.3 P>0.05 9 29.0 
Grade III Nil - Nil -    
Papilledema Nil - Nil -    
Total 22 100.0 9 100.0  31 100.0 
   
The above table -3 explains the fundus changes of hypertensive 
patients and found that there was no significant difference was observed 
between the sexes. Among the hypertensive patients 32.3% was observed 
as normal. Grade I was 38.7% and Grade II was 29%. 
Table -4 Percentage distribution of E.C.G. classification according to 
their sex. 
Male Female Total ECG 
No % No % 
Significance 
No % 
Normal 21 63.6 10 58.8 P>0.05 31 62.0 
LVH 7 21.2 5 29.4 P>0.05 12 24.0 
Hyperakalemia 
(Tall T waves) 
5 15.2 2 11.8 P>0.05 7 14.0 
Total 33 100.0 17 100.0  50 100.0 
  
The table -4 illustrates the E.C.G. results of the study subjects and 
there was no significant difference between the sexes. (P>0.05). The total 
normal cases were 6.2%. The LVH and hyperkalemic changes were 24% 
and 14% respectively. 
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Table -5 Sex wise classification and analysis of creatinine clearance 
among the study subjects. 
Male Female Total Creatinine 
clearance No % No % 
Significance 
No % 
<10 12 36.4 6 35.3 P>0.05 18 36.0 
10 – 20 4 12.1 6 35.3 P>0.05 10 20.0 
20 – 30 8 24.2 4 23.5 P>0.05 12 24.0 
30 – 40 9 27.3 1 5.9 P<0.05 10 20.0 
40 and above Nil - Nil Nil - Nil Nil 
Total 33 100.0 17 100.0 - 50 100.0 
 
From the evaluation of creatinine clearance shown in the table -5 
explains that there was no significant difference between the sexes in 
respect of level of creatinine clearance except the 4th category (30 – 40) 
Among the male patients 12 (36.4%) were having creatinine clearance 
<10 as maximum. Among the female in each category of <10 and 10 -20 
were having 6 (35.3%) as maximum. The male mean creatinine clearance 
was 19.5 11.2 and the same of the female was 15.5 ± 8.9. The difference 
of mean between the sexes was not statistically significant (t = 1.296, d.f 
= 48 and P>0.05). The total mean of clearance of total 50 patients was 
18.1 ±  10.5.  
±
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Table -6 Sex wise percentage distribution of staging of kidney 
diseases. 
Male Female Total Stages of 
Kidney disease No % No % 
Significance 
No % 
Stage – III 9 27.3 1 5.8 P<0.05 10 20.0 
Stage – IV 11 33.3 8 47.1 P>0.05 19 38.0 
Stage - V 13 39.4 8 47.1 P>0.05 21 42.0 
Total 33 100.0 17 100.0  50 100.0 
 
 The above table -6 shows the stages of sex wise relation of C.K.D. 
patients. Since there were no study group belong to stage I and stage II 
they were not included in the table. Among the stage III cases the males 
(27.3%) were greater than the females significantly (P<0.05). But in the 
other two stages the sex differences were not statistically significant 
(P>0.05). Among the total cases, the stage V was greater than other 2 
stages. 
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Table – 7 Percentage distribution of lipid abnormalities in the serum 
sex wise distribution. 
Male n=33 Female n=17 Total n=50 Category  
No % No % 
Significance 
No % 
Raise in TGL 12 36.4 6 35.3 P>0.05 18 36.0 
Raise in LDL 18 54.5 8 47.1 P>0.05 26 52.0 
Raise in  
T.Chl 
5 15.2 4 23.5 P>0.05 9 18.0 
Decrease in  
HDL 
22 66.7 13 76.5 P>0.05 35 70.0 
 
 The above lipid abnormalities among the sex variable of C.K.D 
were furnished in the above table -7. The results of the above analysis 
reveal that there was no significant elevation among the sexes were 
noticed in all lipid elevation namely TGL, LDL and T. cholerterol. The 
decrease of HDL among the sexes were also not significant. Among the 
total cases 36%  have elevated   TGL, 34% have elevated  LDL and 18% 
have  T.Cholesterol. In respect of decrease in HDL among the total cases 
was 70%. 
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Table -8 Stage wise and sex wise elevated TGL classification of study 
subjects. 
Male  Female  Total  Stages  
No % No % 
Significance
No % 
III 2 16.7 0 0 - 2 20.0 
IV 4 33.3 3 50.0 P>0.05 7 38.0 
V 6 50.0 3 50.0 - 9 42.0 
Total 12 100.0 16 100.0 - 18 100.0 
 
The stage wise and sex wise relation of elevated TGL showed in 
the table -8 reveals that there was no significant elevation was observed 
between the sexes (P>0.05) in all stages. The percentage elevated TGL is 
greatest in stage V group in the study. 
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Table – 9 stage wise and sex wise elevated  L.D.L. among the study 
subjects. 
Male  Female  Total  Stages  
No % No % 
Significance 
No % 
III 4 22.2 0 0 - 4 15.4 
IV 4 22.2 4 50.0 P>0.05 8 30.8 
V 10 55.6 4 50.0 P>0.05 14 53.8 
Total 18 100.0 8 100.0 - 26 100.0 
 
 The above table -9 evaluates the elevated level of LDL among the 
study subjects and according to their sex. The elevated level of LDL 
between male and female was not significant (P>0.05) in all stages. The 
percentage elevation in LDL is greatest in stage V CKD than other 
groups. 
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Table -10 Decreased level HDL among the study subjects according 
to their sex and stage. 
Male  Female  Total  Stages  
No % No % 
Significance
No % 
III 5 22.7 1 7.7 P>0.05 6 17.1 
IV 8 36.4 7 53.8 P>0.05 15 42.9 
V 9 40.9 5 38.5 P>0.05 14 40.0 
Total 22 100.0 13 100.0 - 35 100.0 
 
 The above, table -10 reveals the decreased level of HDL among the 
study in relation to male and females sex and found they are of 
statistically not significant (P>0.05). Further the percentage decrease in 
HDL is greatest in stage IV CKD when compared to other stages. 
 
 
 
 
 59
Table-11 Analysis and assessment of sex wise and stage wise LDL 
level in CKD cases. 
 
Male Female Total Stage 
n Mean S.D n Mean S.D 
Mean 
difference 
‘t’ d.f Signi 
ficance 
Mean S.D 
III 9 100.6 37.1 1 59.0 0.0 41.6 3.363 8 P<0.01 96.4 37.4 
IV 11 103.7 56.4 8 124.6 54.8 20.9 0.806 17 P>0.05 112.5 55.2 
V 13 118.3 31.9 8 106.9 49.8 11.4 0.643 19 P>0.05 114.0 38.9 
Total 33 108.6 42.2 17 112.4 51.7 3.8 0.280 48 P>0.05 109.9 45.2 
 
  
The analysis shown in the above table -11 reveals that the mean 
LDL levels of male and female in IIIrd stage were 100.6 ±  37.1 and 59+0 
respectively. The difference was statistically highly significant (P<0.01). 
In other 2 stages the mean LDL values of male and female were 
statistically not significant (P>0.05). The total mean LDL of male was 
108.6  42.2 and the same of the female was 112.4 ± ±  51.7. The total 
LDL levels of both sexes were also not statistically significant (P>0.05). 
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Table -12  Analysis and assessment of TGL in stage wise and sex 
wise. 
Male Female Total Stage 
n Mean S.D n Mean S.D 
Mean 
difference
‘t’ d.f Signi 
ficance Mean S.D 
III 9 133.2 62.1 1 102.0 0.0 31.2 1.507 8 P<0.01 130.1 59.4
IV 11 141.0 55.3 8 148.8 67.2 7.8 0.278 17 P>0.05 144.3 58.9
V 13 162.4 69.4 8 129.5 40.7 32.9 1.212 19 P>0.05 149.8 61.1
Total 33 147.3 62.4 17 136.9 53.6 10.4 0.583 48 P>0.05 143.8 59.2
 
 From the analysis of TGL level among the CKD patients shown in 
the above table  -12 states that the mean TGL levels between the two 
sexes in III stage were 133.2 ±  62.1 and 102.0 ±  0.0 respectively. The 
difference was not statistically significant (P>0.05). Similarly, the other 2 
stages namely IV and V stages, the mean TGL levels between the sexes 
were not statistically significant (P>0.05).  
 
The total TGL levels of the male was 147.3 ±  62.4 and the total 
female mean was 136.9 ±  53.6. The difference between the 2 sexes in 
respect of TGL was not statistically significant. The grand total mean 
TGL was 143.8 ±  59.2. 
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Table -13  Analyses and assessment of HDL level among the C.K.D. 
cases sex wise and stage wise. 
Male Female Total Stage 
n Mean S.D n Mean S.D 
Mean 
difference 
‘t’ d.f Signi 
ficance Mean S.D 
III 9 40.2 8.2 1 30.0 0.0 10.2 1.179 8 P>0.01 39.2 8.4 
IV 11 36.2 7.5 8 39.1 7.5 2.9 0.832 17 P>0.05 37.4 7.4 
V 13 36.0 5.2 8 46.0 9.1 10.0 2.922 19 P<0.05 39.8 8.6 
Total 33 37.2 7.1 17 41.8 9.0 4.6 1.965 48 P>0.05 38.8 8.0 
 
The above HDL analysis in table -13 explains the mean HDL level 
between the sexes in stages of creatinine clearance. In respect of IIIrd and  
IVth stages, there was no significant difference was observed between the 
two sexes (P>0.05). In respect to V stage, the mean HDL of male was 
36.0  5.2 and the same of the female was 46 ± ±  9.1. The difference was 
statistically significant (P<0.05) and inferred that the female were having 
higher level of HDL than the male in the V stage of CKD. The total mean 
HDL level of male was 37.2 ±  7.1 and female mean level was 41.8 + 9.0. 
This difference was not statistically  significant P>0.05. The grand total 
mean HDL level of the study subjects was 38.8 ±  8.0. 
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Table -14  Stage wise comparison of lipid abnormalities. 
Stage III n=10 Stage IV n=19 Stage V n=21 Lipids 
Mean S.D Mean S.D Mean S.D 
Anova  
F 
Significant 
HDL 39.2 8.4 37.4 7.4 39.8 8.6 0.464 P>0.05 
TGL 130.1 59.4 144.3 58.9 149.8 61.1 0.369 P>0.05 
LDL 96.4 37.4 112.5 55.2 114.0 38.9 0.553 P>0.05 
  
The mean HDL in stage III, IV, V patients are 39.2, 37.4, 39.8 
respectively and their S.D. are  8.4, 7.4, 8.6 respectively. The mean TGL 
in stage III, IV, V patient are 130.1, 144.3, 149.8 respectively and their 
S.D are 59.4, 58.9, 61.1 respectively. The mean LDL value  in stage III, 
IV, V are 96.4, 112.5, 114.0 respectively and their S.D are 37.4, 55.2 and 
38.2. From this table, the HDL, TGL, LDL value in stages III, IV, V of 
CKD are not statistically significant (P>0.05) in variation. In other word, 
the inter group  variability of various stages of lipid abnormality are not 
statistically significant. 
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Table -15 Stage wise percentage distribution of alteration in Lipid 
profile. 
 
Stage III Stage IV Stage V Total  Lipid 
No % No % No % No % 
↓ HDL  
n=50 
6 12.0 15 30.0 14 28.0 35 70.0 
↑ TGL 
n=50 
2 4.0 7 14.0 9 18.0 18 36.0 
↑ LDL 
n=50 
2 4.0 7 14.0 8 16.0 17 34.0 
  
The above table shows the stage wise lipid profile alterations. The 
study group comprising HDL found in 6 (12%) in stage III, 15 (30%) in 
stage IV, and 14 (28.0%) in stage V CKD.  The study group comprising 
TGL found in 2 (4.0%) in stage III, 7 (14%) in stage IV, 9 (18%) in 
stage V CKD. The increase in LDL in study group found in 2 (40%) in 
stage III, 7 (14.0%) in stage IV, 8(16.0%) in stage V CKD. ↓ in HDL was 
found in 70% of all stages of CKD study group. 36% pts in all stage of 
CKD study group have increase in TGL. 34% Pts of all stages of CKD 
study group have increase in LDL. From this study the lipid profile 
alteration between the stages in term of percentages were statistically not 
significant (P>0.05). 
↓
↑
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DISCUSSION 
Risk factors for the atherosclerosis are 
1. Central obesity (waist circumference) - >102cms (males) 
>88cms (females) 
2. Hyper Triglyceridemia  >150 mg/dl 
3. Low HDL <40 mg/dl (males), <50mg/dl (females)  
4. Hyper tension >135/85mm Hg 
5. Fasting Blood sugar 110 -125 mgs% 
 
The atherogenic – lipid abnormalities  in chronic kidney disease 
patients were elevated LDL, elevated triglycerides and low HDL. 
 
Impaired maturation of HDL in CKD is primarily due to down 
regulation of lecithin – cholesterol acyltransferase  and to a lesser extent, 
increase plasma cholesteryl ester transfer protein.  Trigylceride 
enrichment of HDL in CKD is due to hepatic lipase deficiency  and 
elevated CETP activity. 
 
The CKD induced Hypertriglyceridemia,  abnormal composition, 
impaired clearance of TGL-rich lipoproteins due to down regulation of 
lipoprotein lipase, hepatic acyl – COA cholesterol acytransferase.  
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The apoprotein present predominantly  in LDL and TGL are apo B 
100. The apoprotein present predominantly  in the HDL are apo A-1, 
which is protective to the atherogenic event. 
 
The apo B48, present predominantly  in the chylomicrons are not 
much atherogenic. 
 
LDL cholesterol – C  contains much more apo B 100 level, which 
is atherogenic,  when this LDL is associated with the high TGL level the 
incidence of atherogenesis  is significantly elevated. Multiple lipid 
abnormalities are more atherogenic. 
 
The study reference was taken from study conducted in 
Department of Nephrology, University of Medicine, Lublin. They 
analysed the lipoprotein profiles  at various stages of chronic kidney 
disease. They have done in 502 pts who are not dialysed prior. Their 
study period was 24mths. According to their study, the significant 
increase of TG, TC, LDL & ↓ HDL were significantly increased in early 
stages of kidney disease and in end stage kidney disease there is not much 
alteration in lipid profile. This is attributed to malnutrition in ESRD in 
that study. 
 
We have taken the ATP III guidelines and the above standard study 
as our reference we had undergone the study and analyzed the results. 
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We had taken the study population from the low socio economic 
status group. After satisfying the inclusion and exclusion criteria we 
analysed the lipid abnormalities in all stages of chronic kidney disease, 
since. We have no study group fits into stage  I and II kidney disease, we 
analyze the other 3 stages of CKD. The decrease in HDL was found to be 
present in stage III, IV and V stages of CKD amounting to 70%  of total.  
The decrease in HDL observed in 3 group (mean 39.2, 37.4, 39.8) 
respectively are not statistically significant in severity when compared 
with stages (P>0.05). Similarly rise in TGL observed in III IV and V 
stage of CKD having mean value (130.1, 144.3, 149.8) respectively are 
not statistically significant in severity when compared with stages 
(P>0.05). The  ↑ in TGL in all stages of CKD amounting to 36% total. 
The rise in LDL obtained in III, IV and Vth stages of CKD having mean 
value (96.4, 112.5, 114.0) respectively, on comparison are not statistically 
significant (P>0.05). Though we found lipid abnormalities in form of 
TGL, LDL and ↓ HDL in study group in all stage of CKD, This 
alteration is not statistically   significant in severity on comparison by 
using this statistical package (S.P.S.S) in form of paired ‘t’ test and anova 
test. 
↑ ↑
The probable reason offered would be a state of malnutrition in low 
social economic status group27.  However large sample size and long 
duration of study would throw more light upon.  
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CONCLUSION 
 
 The study Dyslipidemia in CKD – Correlation to stages of CKD 
An evaluation which was conducted in 50 patients in Medical wards of 
Tirunelveli Medical college Hospital on Non-diabetes kidney disease 
people has revealed that. 
 
1. The lipid abnormalities are found to occur in all stages of 
chronic kidney disease. 
2. The Reduction in HDL is the most observed lipid abnormality. 
3. The lipid abnormalities started to occur even in the earlier 
stages of chronic kidney disease. 
4. However the severity of chronic kidney disease did not correlate 
with the severity of lipid abnormalities and it was found to be 
statistically insignificant. 
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PROFORMA 
 
NAME   
AGE   
SEX IP NO:  
 BASIC DISEASES  
CAHD HT DM 
EDEMA OLIGURIA HEMATURIA 
ABD DISTENSION DYSPNEA FACIAL PUFFINESS 
 G/E  
ANAEMIA SKIN CHANGES  
BP NAIL CHANGES  
 INVESTIGATIONS  
SUGAR   
UREA   
SR. CREATININE   
SR. ELECTROLYTES   
SR.SODIUM   
SR.POTASSIUM   
URINE ALBUMIN   
CREATININE CLEARANCE   
CHEST XRAY PA VIEW   
ECG   
USG KIDNEY SIZE  
 RIGHT  
 LEFT  
SR.LIPID PROFILE   
HDL   
LDL   
VLDL   
TGL   
T.CHOLESTEROL   
 
 78
1 PONNUSAMY 52 M 22357 - 3 - 68 150/100 110 120 9.2 Nil
2 PITCHAMMAL 64 F 35105 - - - 62 130/70 124 81 3.1 Nil
3 MADASAMY 54 M 35208 - - - 66 120/70 90 109 10.2 Nil
4 IBRAHIM MEERAL 62 F 31050 - 4 - 70 140/70 116 119 17 Nil
5 MOOKIAH 54 M 36050 - 6 - 68 140/90 96 280 9.9 Nil
6 VENKATESAN 39 M 36109 - - - 60 120/80 92 58 2.2 ++
7 KALLIAMMAL 45 F 35159 - - - 50 120/80 105 130 6.5 Nil
8 SELVA RAJ 44 M 34422 - 2 - 68 160/110 68 72 3.4 +
9 ROSI 25 F 35086 - - - 48 130/170 95 58 2.8 Nil
10 SOLAI MUTHAMML 59 F 36190 - 2 - 52 160/110 92 178 12.6 Nil
11 MUTHURAMALINGAM 40 M 34682 - 2 - 66 140/110 86 66 3.2 +
12 SUBBAMMAL 54 F 32700 - 3 - 56 140/90 102 120 5.5 Nil
13 PERATCHI 62 F 33742 - 8 - 45 140/100 102 72 2.2 Nil
14 SELVI 23 F 33924 - - - 46 130/80 70 88 3.4 Nil
15 RAJANANI 40 F 33997 - - - 52 140/90 80 116 9.3 Nil
16 LAKSHMANAN 58 M 27771 - 4 - 60 150/110 88 62 3.8 +
17 MUPPIDATHAMMAL 55 F 34325 - 5 - 48 160/100 100 72 2.6 Nil
18 PAULSAMY 40 M 29903 - 4 - 77 140/100 105 168 14.2 Nil
19 KANDASAMY 56 M 29892 - 3 - 45 145/100 79 81 4.4 Nil
20 SUBBULAKSHMI 45 F 42356 - - - 62 120/70 106 60 2.6 +
21 MALSAMY 65 M 30921 - - - 62 90/60 108 72 2.9 Nil
22 MUPPIDATHI 55 M 24925 - 4 - 54 190/100 89 178 17 Nil
23 ABULJOTHI 33 F 34603 - 1 - 60 110/100 87 189 5.8 Nil
24 MADASAMY 51 M 34870 - 3 - 70 150/110 118 78 2.6 ++
25 PARAMASIVAM 61 M 34195 - 4 - 58 140/90 102 333 16 Nil
26 RASOOL MOHAMMED 48 M 22396 - 4 - 70 170/100 62 150 9.2 Nil
27 MARAGATHAMMAL 44 F 22470 - - - 66 110/70 96 85 3.6 Nil
28 ARUMUGA RAJA 18 M 36933 - - - 46 140/90 50 271 21 Nil
29 SUBRAMANIYAN 65 M 37335 - - - 68 120/70 104 160 3.2 Nil
30 SIVANAND 65 M 36923 - - - 64 130/80 101 121 4.4 Nil
31 MURUGAN 57 M 44168 - 5 - 62 160/100 106 99 3.3 Nil
32 PANDI 52 M 31922 - 4 - 66 180/100 92 48 2.6 Trece
33 CHELLIAH 65 M 50450 - - - 62 110/70 94 88 2.3 +
34 GOMATHI NAYAGAM 57 M 50384 - 4 - 55 110/110 96 82 3.2 Nil
35 CHELLATHAI 64 F 54356 - 6 - 54 140/90 106 198 7.3 Nil
36 ALAGAR 30 M 58476 - - - 62 150/100 68 110 5.5 Nil
37 ESAKIMUTHU 40 M 51427 - - - 64 1730/70 94 64 2.9 +
38 LEELAVATHI 45 F 16342 - 3 - 66 140/100 146 66 2.8 +
39 JOHN 54 M 53946 - 4 - 68 160/100 112 68 3.1 +
40 KETTIPOMMU 64 F 55226 - 5 - 50 130/100 87 55 2.3 Trece
41 MARIAPPAN 32 M 54523 - 1 - 56 140/104 71 201 14.6 Nil
42 JEGAVEERA PANDIAN 59 M 38285 - 3 - 76 100/100 91 46 2.8 +
43 RAJESWARI 30 M 38006 - - - 52 120/70 86 105 19.5 Nil
44 PITCHIAH 68 M 39076 - - - 18 140/80 104 209 8.4 Nil
45 DEVARAJ 65 M 36720 - 4 - 66 160/100 65 68 2.8 ++
46 SIVANAND 48 M 39326 - 7 - 70 170/100 113 86 3.2 Nil
47 PERIYA KARUPAMY 60 M 40428 - 6 - 68 140/100 60 72 2.3 ++
48 AGUSTIN 46 M 38294 - 4 - 64 160/100 75 64 2.6 +
49 PONNUSAMY 52 M 22537 - 5 - 64 150/100 110 120 9.2 Nil
50 PONNAMMAL 17 F 40872 - - - 42 130/90 68 177 10 Nil
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WT BP SUGAR UREA CREAT URINE ALB
Sl.
No. NAME AGE SEX IP NO DM HT CAHD
R.K
in cms
L.K
in cms HDL LDL VLDL TGL T.CHOL
1 137 3.6 8.5 Gr II N 7.8x3.4 8.2x3.6 37 144 23 114 204
2 144 5.1 17.9 N N 9.0x3.3 8x4.1 39 86 50 250 175
3 140 5.9 7.7 N TALLT 6.4x3.3 7x4 46 62 29 144 137
4 141 5.5 3.8 Gr II N 6.8x4.2 7.4x4.4 53 157 34 171 244
5 125 3.7 8.2 Gr I LVH 8.3x3.6 8.6x2.7 30 124 44 222 110
6 128 3.4 38.3 N N 7.9x3.3 8.1x3.6 49 110 19 86 176
7 134 4.5 8.6 N N 6.9x4.19 7.9x3.2 57 95 31 157 177
8 143 5.8 26.7 Gr I LVH 6.6x4.2 7.5x3.2 28 88 13 65 129
9 54 2.2 33 N TALLT 6x3 5.6x2.3 30 59 20 102 109
10 126 4.5 3.9 Gr I LVH 7.7x3.2 8.6x3.4 31 66 19 95 116
11 146 5.6 28.6 Gr I N 5.6x3.4 7.5x3.2 51 75 30 151 156
12 141 4.2 10.3 N LVH 9.4x4.2 9x4.2 46 133 27 133 189
13 58 2.4 18.8 Gr II LVH 8.2x3.6 8.4x4.2 40 56.8 19.8 99 77
14 133 4.9 18.7 N TALLT 6.9x2.1 7.7x2.8 40 151 15 115 176
15 136 5.4 6.6 Gr II N 9.2x3.6 9.5x3.4 38 171.2 37.2 186 132
16 122 6 24.4 Gr I N 6.2x3.6 5.8x3.2 42 77 21 103 98
17 122 4 18.5 Gr II LVH 3.6x6.3 9.1x7.2 46 80 20 101 46
18 119 4.8 7.2 Gr II LVH 5.2x2.6 7.6x3.1 30 120 54 269 204
19 143 5.4 11.9 N LVH 8.2x3.6 8.6x4.2 42 117 14 72 173
20 140 3.8 26.7 N N 8.6x3.2 8.4x3.6 26 97 30 102 143
21 131.2 4.5 22.3 N N 7.2x3.6 8.6x3.4 38 53 29 146 120
22 162 5.8 3.8 Gr I TALLT 6.4x3.6 5.8x3.2 40 85 52 260 177
23 132 4 13.5 N N 9.8x3.8 8.8x4.2 41 57 27 130 145
24 134.7 3.8 33.3 N N 6.2x3.4 5.9x3.1 36 89 16 81 141
25 142 6.5 4 N LVH 5x2.6 7.8x3.1 41 119 37 188 123
26 134.6 4.6 9.7 Gr II LVH 7.2x3.2 7.0x2.7 33 110 40 250 183
27 129 4.2 20.8 N N 8.6x4.2 8.8x4.4 50 125 40 199 215
28 137.2 3.7 3.7 N N 7.4x3.4 7.8x3.4 42 176 46 232 172
29 140 2.5 22.1 N N 7.5x3 7.8x3.9 44 70 55 274 169
30 140 4.5 15.2 N N 7.0x2.5 7.0x2.7 33 44 28 142 105
31 131 3.3 21.7 Gr II N 8.6x4.2 8.8x4.3 34 216.8 36.8 184 214
32 141 5 31 N LVH 7.7x3.2 6.6x2.7 46 131 20 99 197
33 129 3.8 28.1 N N 8.8x2.2 8.2x4.6 42 147 27 138 162
34 123 4.6 19.8 Gr II N 9.2x4.4 9.2x3.8 24 60 20 102 104
35 122 3.7 6.6 N LVH 8.6x4.2 8.8x4.3 55 38 14 32 107
36 138 4.5 16.9 N N 8.8x4.2 8.4x3.9 38 176 46 202 174
37 137 3.7 30.7 N N 9.2x4.2 8.8x3.8 36 168 36 182 168
38 109 3.4 26.4 Gr II N 8.6x4.2 8.8x4.2 32 200 44 224 188
39 136 5.6 26.2 Gr I TALLT 8.4x4.2 8.2x2.2 38 134 14 71 186
40 142 4.9 23.4 Gr II N 8.6x4.6 2.8x4.6 40 201 18 90 259
41 125 5 5.8 N N 7.8x3.6 6.8x2.7 30 107 16 80 155
42 139 4.5 30.5 N N 6.9x3.2 6.6x3.9 54 126 20 101 200
43 121 5.5 3.5 N N 7.6x3.4 6.6x2.7 36 154 24 124 165
44 146 3.7 2.1 N N 7.7x3.2 6.6x2.7 27 76 19 92 122
45 144 4.3 31.2 N N 7.7x3.2 6.6x2.7 34 46 27 136 157
46 141 4.7 28 Gr II TALLT 8.4x4 8.8x4.4 30 70 49 247 149
47 140 5.2 32.9 Gr II N 9.2x4.2 9.4x4.4 32 99 29 144 103
48 137 6.2 32.1 Gr I TALLT 7.3x3.6 7.7x3.8 31 75 19 96 125
49 137 3.6 8.5 Gr II N 8.4x4 8.6x4.6 37 144 23 114 204
50 128 3.5 6.1 N N 7.6x3.2 6.6x2.6 48 138 18 92 204
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SR. LIPID PROFILE
ECG
USG      ABD
NA + K + CR.CLEARANCE FUNDUSSl.No. 
